Volume : 12, Issue : 03, March – 2025
Title:
INNOVATIVE PHARMACOLOGICAL APPROACHES FOR TREATING GASTROINTESTINAL TRACT (GIT) DISORDERS: A COMPREHENSIVE REVIEW
Authors :
Sarvesh Tryambak Lawange, Sunil S. Bhagat, Dr. Swati P. Deshmukh
Abstract :
Gastrointestinal tract (GIT) disorders, including irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), and inflammatory bowel disease (IBD), significantly affect millions of people worldwide, leading to chronic pain, digestive dysfunction, and reduced quality of life. Current pharmacological treatments primarily focus on symptom management rather than addressing underlying causes. Recent advances in molecular medicine, gene therapy, microbiome research, and nanomedicine have introduced innovative therapeutic strategies for GIT disorders. This review explores cutting-edge pharmacological interventions, including biologics, small-molecule inhibitors, RNA-based therapies, probiotics, and nanotechnology-driven drug delivery systems. Additionally, challenges related to drug bioavailability, patient adherence, and regulatory approvals are discussed. By presenting a comprehensive overview of these novel approaches, this review aims to highlight the future of GIT disorder management.
Keywords: Gastrointestinal disorders, Nanomedicine, Gut microbiome, Biologics, Gene therapy
Cite This Article:
Please cite this article in press Sunil S. Bhagat et al., Innovative Pharmacological Approaches For Treating Gastrointestinal Tract (Git) Disorders: A Comprehensive Review., Indo Am. J. P. Sci, 2025; 12 (03)
Number of Downloads : 10
References:
1. Jablonska B, Mrowiec S. Gastrointestinal disease: new diagnostic and therapeutic approaches. Biomedicines. 2023;11(5):1420.
2. Prasad K, Bansal D. Modern trends in the management of gastroesophageal reflux disease in India. Indian J Gastroenterol Hepatol. 2022;42(1):23–9.
3. Turnbaugh PJ, Gordon JI. The core gut microbiome, energy balance, and obesity. J Clin Invest. 2009;119(5):1213–21.
4. Lee C, Park S. Advances in CRISPR-based gene editing for gastrointestinal disorders. Nat Rev Gastroenterol Hepatol. 2022;19(3):142–56.
5. Cani PD, Everard A. Gut microbiota composition and its influence on host metabolism. Curr Opin Clin Nutr Metab Care. 2016;19(1):49–55.
6. Gut-brain axis modulation for IBS: A review of the current evidence. Journal Clinical Psychopharmacol. 2021;41(5):541-8. Doi:10.1097/JCP.
7. Microbiome-targeted therapies for IBS: A systematic review. Journal Clinical Gastroenterology. 2020;54(8):558-66. Doi: 10.1097/MCG.
8. Novel therapies for gastrointestinal motility disorders: A review of the current landscape. Expert Opin Pharmacother. 2020;21(14):1645-55.
9. Devereaux M, Lacy BE. Advances in the pharmacological management of irritable bowel syndrome. Gastroenterology. 2020;158(5):1232-43. Doi: 10.1053/j.gastro.2020.01.044.
10. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Infect Dis doi: 10.1016/j.idc.2017.04.007. Clin North Am. 2017:31(3):473-96.
11. Innovative pharmacological strategies for irritable bowel syndrome. Expert Opin Pharmacother. 2022;23(10):1241-53. Doi: 10.1080/14656566.2022.2086424.
12. Advances in pharmacological management of gastrointestinal motility disorders. Journal on Clinical Pharmacology. 2021;61(9):1239-48. Doi:10.1002/jcph. 1845.
13. Pharmacological approaches to gut-brain axis modulation. European Journal on Neuroscience. 2020;52(6):3421-34. Doi:10.1111/ejn.14823.
14. Emerging therapies for inflammatory bowel disease. Journal on Clinical Gastroenterology. 2022;56(6):539-47. Doi: 10.1097/MCG.0000000000001451.
15. Small molecule inhibitors for IBD: A review of the current status. European Journal Pharmacol. 2021:882:173835. Doi:10.1016/j.ejphar.